ECM
MYGN icon

ExodusPoint Capital Management’s Myriad Genetics MYGN Stock Holding History

ExodusPoint Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-313,370
Closed -$1.93M – 1903
2025
Q4 		$1.93M Buy
313,370
+291,830
+1,355% +$2.12M 0.02% 781
2025
Q3 		$156K Sell
21,540
-40,144
-65% -$238K ﹤0.01% 1409
2025
Q2 		$328K Sell
61,684
-87,009
-59% -$514K ﹤0.01% 1230
2025
Q1 		$1.32M Buy
+148,693
New +$1.79M 0.01% 841
2024
Q3 		– Sell
-170,287
Closed -$4.17M – 1927
2024
Q2 		$4.17M Buy
170,287
+91,221
+115% +$2M 0.03% 471
2024
Q1 		$1.69M Buy
+79,066
New +$1.7M 0.01% 770
2023
Q4 		– Sell
-17,960
Closed -$288K – 1850
2023
Q3 		$288K Sell
17,960
-343,657
-95% -$6.54M ﹤0.01% 1429
2023
Q2 		$8.38M Buy
+361,617
New +$7.89M 0.07% 290
2023
Q1 		– Sell
-12,300
Closed -$178K – 2001
2022
Q4 		$178K Buy
+12,300
New +$229K ﹤0.01% 1474
2021
Q1 		– Sell
-23,437
Closed -$463K – 2429
2020
Q4 		$463K Buy
+23,437
New +$378K ﹤0.01% 1302
2020
Q3 		– Sell
-36,839
Closed -$418K – 2065
2020
Q2 		$418K Buy
+36,839
New +$523K 0.01% 1165

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ExodusPoint Capital Management's MYGN Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 313,370 shares — an estimated $1.93M sold.

ExodusPoint Capital Management first reported a position in MYGN in Q2 2020 and held it in 11 quarters. The position peaked at $8.38M in Q2 2023. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 313,370 Myriad Genetics shares in Q1 2026, an estimated $1.93M.
  • ExodusPoint Capital Management first reported a position in Myriad Genetics in Q2 2020 and held it in 11 quarters.
  • ExodusPoint Capital Management's Myriad Genetics position peaked at $8.38M in Q2 2023.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.